Search

Displaying results 3481 - 3490 of 10000 in total
  1. Drug

    Antihemophilic factor, human recombinant

    go.drugbank.com/drugs/DB00025
    ApprovedInvestigational

    Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells

  2. Drug

    Hydroxycitronellal

    go.drugbank.com/drugs/DB14187
    Approved

    Hydroxycitronellal is a synthetic fragrance that is widely used in many cosmetics and hygiene products such as deodorants, soaps, antiseptics, and other household items.

  3. Drug

    Lobeline

    go.drugbank.com/drugs/DB05137
    Investigational

    It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem] … An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent.

  4. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    [A253292,A253297,L43557] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended tabelecleucel be granted marketing authorization for the treatment of adult and … Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs).

  5. Drug

    Adefovir dipivoxil

    go.drugbank.com/drugs/DB00718
    Approved

    Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment

  6. Drug

    Dimetotiazine

    go.drugbank.com/drugs/DB08967
    Approved

    Dimetotiazine has considerable antiemetic & serotonin antagonistic action used mainly in allergic skin conditions.

  7. Drug

    EVT 302

    go.drugbank.com/drugs/DB06057
    Investigational

    EVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

  8. Drug

    CYT007-TNFQb

    go.drugbank.com/drugs/DB05758
    Experimental

    The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules. … CYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis.

  9. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk … restricted expression on normal tissues.

  10. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    [L63350] It is available only in fixed combination with [cefepime], which binds PBP3 and PBP1a/b. … Zidebactam is a diazabicyclooctane that acts both as a beta-lactamase inhibitor and as an antibacterial in its own right, selectively binding penicillin-binding protein 2.